Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Drug Toxicity: Allergic Reactions

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

Diphtheria

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A comparative analysis of routine hospital admission data for sickle cell anaemia, cystic fibrosis and haemophilia in England.

Scientific reports·2026

Same author

Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association.

Stroke·2026

Same author

Clinical Pharmacists and Industry: Guidelines for Professional Interactions.

Journal of the American College of Clinical Pharmacy : JACCP·2026

Same author

Ethnic inequality in prostate cancer: no current role for screening but hope for the future.

BMJ (Clinical research ed.)·2026

Same author

Characterising the contribution of inhalational exposures in interstitial lung disease.

Thorax·2025

Same author

Indicators of inequity in research and funding for sickle cell disease, cystic fibrosis and haemophilia: a descriptive comparative study.

The Lancet. Haematology·2025

Search research articles

Related Experiment Video

Updated: May 14, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Rash associated with dabigatran etexilate.

Kim To¹, Carl Reynolds, Sarah A Spinler

¹Philadelphia College of Pharmacy University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA.

Pharmacotherapy

|February 13, 2013

Summary

Dermatologic reactions, such as rash, are a rare but possible adverse effect of dabigatran etexilate, an anticoagulant used for atrial fibrillation. This case highlights the importance of monitoring patients for skin reactions during therapy.

Related Experiment Videos

Last Updated: May 14, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Area of Science:

Pharmacology
Dermatology
Cardiology

Background:

Atrial fibrillation increases thromboembolic risk, necessitating anticoagulation therapy.
Dabigatran etexilate, approved in 2010, is used for stroke prevention in nonvalvular atrial fibrillation.
Dermatologic reactions to dabigatran etexilate are reported in less than 0.1% of patients.

Observation:

A 59-year-old male patient developed a rash after 5 days of dabigatran etexilate therapy for atrial flutter.
The patient had no prior drug allergies, and his lab results (platelets, creatinine, liver function) were normal.
The rash resolved within 7 days of discontinuing dabigatran etexilate.

Findings:

This report details the sixth case of dabigatran etexilate-associated rash, with a probable relationship indicated by the Naranjo scale.
The patient was successfully transitioned to warfarin therapy after the adverse event.
The study contributes to the limited published data on dabigatran etexilate-induced dermatologic reactions.

Implications:

Clinicians should maintain awareness of potential dermatologic adverse effects associated with dabigatran etexilate.
Vigilant monitoring for skin reactions during patient follow-up is recommended.
This case underscores the need for comprehensive adverse event reporting in pharmacovigilance.